Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
News from American Society of Clinical Oncology Meeting June 2011 (Lung and Skin) Paul Donnellan Consultant Medical Oncologist Galway University Hospitals 1 Common causes of cancer death in the United States, 2008 ©2009 by American Association for Cancer Research Rudin C M et al. Clin Cancer Res 2009;15:5622-5625 Figure 3.1: Age-standardised (European) incidence rates for all cancers excluding Persons Incidence Persons Mortality 450 400 300 250 200 150 100 50 Year of diagnosis/death 2007 2005 2003 2001 1999 1997 1995 1993 1991 1989 1987 1985 1983 1981 1979 1977 0 1975 Rate per 100,000 350 Melanoma: Mortality 4 Clinical Images of Pigmented Lesions Tsao, H. et al. N Engl J Med 2004;351:998-1012 Metastatic Melanoma Young age at onset Dismal prognosis – 1yr survival 25%; – 2yr survival 10% (Korn et al JCO 2008) Chemotherapy ineffective – Dacarbazine (DTIC) response rates 10% median survival < 8 months Never shown to improve survival 7 High Dose Interleukin-2 • 16% respond (6% completely and for median duration 10 yrs) Immune ERU… . Kirkwood J M et al. JCO 2008;26:3445-3455 Kaplan–Meier Curves for Overall Survival and Progression-free Survival in the Intention-toTreat Population Hodi FS et al. N Engl J Med 2010;363:711-723 Intracellular Signaling Pathways in Melanoma Known to Be Important in the Response and Resistance to Targeted Therapy. Smalley KS, Sondak VK. N Engl J Med 2010;363:876878. Targeting Treatment to a Specific Variant in the Melanoma Gene. McDermott U et al. N Engl J Med 2011;364:340-350. Best Tumor Response for Each Patient. Chapman PB et al. N Engl J Med 2011. DOI: 10.1056/NEJMoa1103782 Chapman PB et al. N Engl J Med 2011. DOI: 10.1056/NEJMoa1103782 A 72-year-old man presented for evaluation of progressive dyspnea and cough McMullan, D. M. et al. N Engl J Med 2006;354:397 Smoking image Lung Cancer Tarceva • Tablet once a day • Few side effects • If have the target mutation, the response to treatment is 5 times higher than with chemotherapy! •55% vs 11% Crizotinib • Tablet once a day • Targets EML4-ALK (5% on NSCLC) • Few side effects • Dramatic response in patients who have failed chemotherapy • 90% patients respond • Randomised Clinical Trial UCHG